Company / SG&A per Share
RAPT Therapeutics, Inc. SG&A per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.71
FY2024
5-year range
$0.53 / $0.71
FY2020-FY2024
Trend
+4.2%
vs FY2023
Sector context
#146 of 206
Health Care
What the data says
At $0.71, RAPT Therapeutics, Inc.'s sg&a per share ranks #61 of 206 in the Health Care sector. SG&A per Share has increased for 4 consecutive years, from $0.53 in FY2020 to $0.71 in FY2024.
Based on SEC 10-K filings.
0.71 in FY2024 with a 5-year CAGR of -18.8%.
Increased from $0.62 to $0.71 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +6.6%
- 5-Year CAGR
- -18.8%
- 10-Year CAGR
- -
Sector benchmark
#61 of 206 in Health CareTop 29% of 206This company $0.71 Sector average $44.68
▼
-98.4% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s sg&a per share has grown for 4 consecutive years.
- In FY2024, sg&a per share increased 4.2% year-over-year.
- Ranks #146 out of 206 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.71 | +4.2% |
| FY2023 | $0.68 | +9.3% |
| FY2022 | $0.62 | +6.2% |
| FY2021 | $0.59 | +10.6% |
| FY2020 | $0.53 | -73.6% |
| FY2019 | $2.01 | -75.9% |
| FY2018 | $8.32 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026